Antidepressive Agents

"Antidepressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Descriptor ID	D000928
MeSH Number(s)	D27.505.954.427.700.122
Concept/Terms	Antidepressive Agents Antidepressive Agents Agents, Antidepressive Antidepressant Drugs Drugs, Antidepressant Antidepressants Thymoanaleptics Thymoanaleptics Thymoleptics Thymoleptics

Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Psychotropic Drugs [D27.505.954.427.700]
Antidepressive Agents [D27.505.954.427.700.122]

Below are MeSH descriptors whose meaning is related to "Antidepressive Agents".

Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents".

Antidepressive Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents, Tricyclic

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antidepressive Agents" by people in this website by year, and whether "Antidepressive Agents" was a major or minor topic of these publications.

Bar chart showing 45 publications over 20 distinct years, with a maximum of 5 publications in 2005 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	1	2
2000	1	0	1
2004	1	0	1
2005	2	3	5
2006	0	1	1
2007	0	1	1
2009	1	3	4
2010	2	1	3
2011	2	1	3
2012	3	2	5
2013	1	1	2
2014	1	0	1
2016	0	1	1
2017	2	2	4
2018	3	0	3
2019	2	1	3
2020	1	0	1
2021	0	1	1
2022	0	2	2
2023	0	1	1

Below are the most recent publications written about "Antidepressive Agents" by people in Profiles.

Chang CY, Park H, Hincapie-Castillo JM, Heldermon CD, Diaby V, Yang S, Wilson DL, Lo-Ciganic WH. Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression. J Manag Care Spec Pharm. 2023 Apr; 29(4):431-445.

View in: PubMed
Korthauer LE, Goveas JS, Rapp SR, Espeland MA, Shumaker SA, Garcia KR, Rossom RC, Garcia L, Tindle HA, Salmoirago-Blotcher E, Wassertheil-Smoller S, Zaslavsky O, Cochrane B, Sink KM, Masaki K, Driscoll I. The relationship between depressive symptoms and subtypes of mild cognitive impairment in post-menopausal women: Results from the Women's Health Initiative Memory Study. Int J Geriatr Psychiatry. 2022 11; 37(11).

View in: PubMed
Healy D, Bahrick A, Bak M, Barbato A, Calabr? RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJG, Irwig MS, Jannini EA, Janssen PKC, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DEJ, L?ning C, Mangin D, Melcangi RC, Rodr?guez OWMAAS, Panicker JN, Patacchini A, Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Va?eckov? B, Waraich A. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022; 33(1):65-76.

View in: PubMed
McCarthy MJ, Chen Y, Demodena A, Leckband SG, Fischer E, Golshan S, Suppes T, Kelsoe JR. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol. 2021 Aug; 35(8):992-1002.

View in: PubMed
Reddy HM, Poole JS, Maguire GA, Stahl SM. New Medications for Neuropsychiatric Disorders. Psychiatr Clin North Am. 2020 06; 43(2):399-413.

View in: PubMed
Lu BY, Agapoff JR, Olson DJ, Williams SR, Roller A, Goebert D. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. J Affect Disord. 2020 02 01; 262:40-42.

View in: PubMed
Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL. Novel targets for parkinsonism-depression comorbidity. Prog Mol Biol Transl Sci. 2019; 167:1-24.

View in: PubMed
Getachew B, Mendieta L, Csoka AB, Aguilera J, Tizabi Y. Antidepressant effects of C-Terminal domain of the heavy chain of tetanus toxin in a rat model of depression. Behav Brain Res. 2019 09 16; 370:111968.

View in: PubMed
Iyer AS, Holm KE, Bhatt SP, Kim V, Kinney GL, Wamboldt FS, Jacobs MR, Regan EA, Armstrong HF, Lowe KE, Martinez CH, Dransfield MT, Foreman MG, Shinozaki G, Hanania NA, Wise RA, Make BJ, Hoth KF. Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. J Psychosom Res. 2019 03; 118:18-26.

View in: PubMed
Getachew B, Aubee JI, Schottenfeld RS, Csoka AB, Thompson KM, Tizabi Y. Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties. BMC Microbiol. 2018 12 22; 18(1):222.

View in: PubMed

People

Explore

Similar Concepts

Top Journals